How does flavivirus cross-reactivity affect Zika test selection in dengue-endemic hospitals?

Shared IgM epitopes between Zika and dengue produce serological false-positive rates exceeding 40% in co-endemic zones [9]. Hospitals in these settings should default to molecular confirmation rather than standalone serology. Read More

What shelf-life challenges do rapid Zika tests face in tropical supply chains?

Lateral-flow cassettes degrade when stored above 30°C, cutting effective shelf life from 24 months to roughly 10 months [10]. Lyophilized reagent formats are emerging to address ambient-stability gaps. Read More

Which US reimbursement codes cover Zika virus testing?

CPT codes 87662 (Zika RT-PCR) and 86794 (Zika IgM antibody) are the primary billing pathways [6]. Commercial payer coverage varies by state and clinical indication. Read More

Can CRISPR-based diagnostics replace RT-PCR for Zika detection by 2030?

CRISPR-Cas13 platforms match RT-PCR sensitivity at attomolar concentrations without thermocycling [12]. Regulatory approval timelines and manufacturing scale-up will determine whether displacement occurs before 2032. Read More

How should procurement teams compare multiplex versus single-target Zika assays?

Multiplex panels reduce per-pathogen cost by 30–35% but require higher upfront instrument investment [3]. Single-target kits remain preferable where only Zika confirmation is clinically indicated. Read More

What biosafety requirements apply to handling live Zika virus in research laboratories?

Propagation of live Zika virus requires BSL-2 facilities with BSL-3 practices per CDC guidelines [6]. Clinical specimen processing for diagnostic purposes operates under standard BSL-2 precautions. Read More

Are dried blood spot methods viable for Zika surveillance in remote field settings?

Dried blood spots preserve Zika RNA for up to 28 days at ambient temperature, enabling specimen transport without cold-chain infrastructure [2]. Sensitivity is approximately 85–90% relative to fresh serum. Read More

Zika Virus Testing Market

ID: MRFR/LS/4207-HCR

100 Pages

Rahul Gotadki

Last Updated: June 22, 2026

Zika Virus Testing Market Research Report Information By Tests Include (serological/Zika virus antibody and molecular/nucleic acid amplification), End-Users (Diagnostic units, hospitals, pathology labs), Regions (Asia Pacific, Europe, Americas, and the Middle East and Africa) Forecast till 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Takeaways
3 Market Dynamics |
1. 3.1 Market Drivers Analysis | |
  1. 3.1.1 Climate-Driven Aedes Vector Expansion | |
  2. 3.1.2 Multiplex Molecular Platform Adoption | |
  3. 3.1.3 Blood-Bank Zika Screening Mandates | |
  4. 3.1.4 WHO Arboviral Surveillance Protocols | |
  5. 3.1.5 POC Rapid-Test Decentralization | |
  6. 3.1.6 AI-Assisted Assay Design Reducing Cross-Reactivity | |
  7. 3.1.7 International Travel Recovery and Zika Re-Importation Risk |
2. 3.2 Market Restraints Analysis | |
  1. 3.2.1 Serological Cross-Reactivity with Dengue/Flaviviruses | |
  2. 3.2.2 Cold-Chain Logistics in Tropical Regions | |
  3. 3.2.3 Intermittent Outbreak Cycles Dampening Steady Procurement | |
  4. 3.2.4 Regulatory Fragmentation Across National IVD Frameworks | |
  5. 3.2.5 Limited Reimbursement Pathways in Low-Income Settings |
3. 3.3 Market Opportunity Analysis | |
  1. 3.3.1 CRISPR-Based Diagnostics for Field Deployment | |
  2. 3.3.2 Saliva-Based Self-Collection Kits for Home Testing | |
  3. 3.3.3 Data-Monetization Through Syndromic Surveillance Platforms | |
  4. 3.3.4 Emerging-Market Laboratory Upgrades | |
  5. 3.3.5 Dual-Use Travel-Health Testing Panels |
4. 3.4 Industry Value Chain Analysis |
5. 3.5 Porter's Five Forces Analysis
4 Global Zika Virus Testing Market Size & Forecast (2021–2035) |
1. 4.1 Historical Market Size (2021–2025) |
2. 4.2 Current & Forecast Market Size (2026–2035) |
3. 4.3 Market Size by Revenue (USD Million) |
4. 4.4 Year-over-Year Growth Analysis
5 Segmentation Analysis |
1. 5.1 By Test Type | |
  1. 5.1.1 Molecular Tests | |
  2. 5.1.2 Serologic Tests | |
  3. 5.1.3 PRNT |
2. 5.2 By Sample Type | |
  1. 5.2.1 Blood/Serum | |
  2. 5.2.2 Urine | |
  3. 5.2.3 Saliva & Others |
3. 5.3 By End-User | |
  1. 5.3.1 Hospitals & Clinics | |
  2. 5.3.2 Public-Health/Diagnostic Laboratories | |
  3. 5.3.3 Point-of-Care Settings & Home Testing | |
  4. 5.3.4 Research Institutes
6 Regional Analysis |
1. 6.1 North America | |
  1. 6.1.1 United States | |
  2. 6.1.2 Canada | |
  3. 6.1.3 Mexico |
2. 6.2 Europe | |
  1. 6.2.1 Germany | |
  2. 6.2.2 United Kingdom | |
  3. 6.2.3 France | |
  4. 6.2.4 Italy | |
  5. 6.2.5 Spain | |
  6. 6.2.6 Nordic Countries | |
  7. 6.2.7 Russia | |
  8. 6.2.8 Rest of Europe |
3. 6.3 Asia-Pacific | |
  1. 6.3.1 China | |
  2. 6.3.2 India | |
  3. 6.3.3 Japan | |
  4. 6.3.4 South Korea | |
  5. 6.3.5 ASEAN | |
  6. 6.3.6 Rest of Asia-Pacific |
4. 6.4 South America | |
  1. 6.4.1 Brazil | |
  2. 6.4.2 Argentina | |
  3. 6.4.3 Rest of South America |
5. 6.5 Middle East & Africa | |
  1. 6.5.1 Saudi Arabia | |
  2. 6.5.2 UAE | |
  3. 6.5.3 South Africa | |
  4. 6.5.4 Egypt | |
  5. 6.5.5 Rest of MEA
7 Competitive Landscape |
1. 7.1 Market Share Analysis (2025) |
2. 7.2 Competitive Benchmarking Matrix |
3. 7.3 Company Profiles | |
  1. 7.3.1 Hologic, Inc. | |
  2. 7.3.2 Abbott Laboratories | |
  3. 7.3.3 Roche Diagnostics | |
  4. 7.3.4 Quest Diagnostics | |
  5. 7.3.5 Bio-Rad Laboratories | |
  6. 7.3.6 bioMérieux SA | |
  7. 7.3.7 Siemens Healthineers | |
  8. 7.3.8 Chembio Diagnostics | |
  9. 7.3.9 Euroimmun (Revvity) | |
  10. 7.3.10 InBios International
8 Future Outlook & Strategic Recommendations (2026–2035) |
1. 8.1 AI-Integrated Assay Development |
2. 8.2 Decentralized and Connected Diagnostics |
3. 8.3 Climate-Adaptation Surveillance Economics |
4. 8.4 Pandemic-Preparedness Supply-Chain Resilience
9 Recent Developments & News
10 Frequently Asked Questions (FAQs)
11 Report Scope & Methodology |
1. 11.1 Study Period & Base Year |
2. 11.2 Data Sources & Citations |
3. 11.3 Abbreviations
12 LIST OF TABLES |
TABLE 1 Global Zika Virus Testing Market Size & Forecast, by Revenue (USD Million), 2021–2035 |
TABLE 2 Global Zika Virus Testing Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Global Zika Virus Testing Market — Driver Impact Analysis |
TABLE 4 Global Zika Virus Testing Market — Restraints Impact Analysis |
TABLE 5 Global Zika Virus Testing Market Size, by Test Type, 2021–2035 (USD Million) |
TABLE 6 Global Zika Virus Testing Market Size, by Sample Type, 2021–2035 (USD Million) |
TABLE 7 Global Zika Virus Testing Market Size, by End-User, 2021–2035 (USD Million) |
TABLE 8 Global Zika Virus Testing Market Size, by Region, 2021–2035 (USD Million) |
TABLE 9 North America Zika Virus Testing Market Size, by Country, 2021–2035 (USD Million) |
TABLE 10 Europe Zika Virus Testing Market Size, by Country, 2021–2035 (USD Million) |
TABLE 11 Asia-Pacific Zika Virus Testing Market Size, by Country, 2021–2035 (USD Million) |
TABLE 12 South America Zika Virus Testing Market Size, by Country, 2021–2035 (USD Million) |
TABLE 13 Middle East & Africa Zika Virus Testing Market Size, by Country, 2021–2035 (USD Million) |
TABLE 14 Competitive Benchmarking Matrix — Global Zika Virus Testing Market, 2025 |
TABLE 15 Company Profiles — Key Players, Global Zika Virus Testing Market |
TABLE 16 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 17 Report Scope & Methodology Summary |
TABLE 18 Detailed Sources and Citations |
TABLE 19 North America Zika Virus Testing Market Size, by Test Type, 2021–2035 (USD Million) |
TABLE 20 North America Zika Virus Testing Market Size, by Sample Type, 2021–2035 (USD Million) |
TABLE 21 North America Zika Virus Testing Market Size, by End-User, 2021–2035 (USD Million) |
TABLE 22 Europe Zika Virus Testing Market Size, by Test Type, 2021–2035 (USD Million) |
TABLE 23 Europe Zika Virus Testing Market Size, by Sample Type, 2021–2035 (USD Million) |
TABLE 24 Europe Zika Virus Testing Market Size, by End-User, 2021–2035 (USD Million) |
TABLE 25 Asia-Pacific Zika Virus Testing Market Size, by Test Type, 2021–2035 (USD Million) |
TABLE 26 Asia-Pacific Zika Virus Testing Market Size, by Sample Type, 2021–2035 (USD Million) |
TABLE 27 Asia-Pacific Zika Virus Testing Market Size, by End-User, 2021–2035 (USD Million) |
TABLE 28 South America Zika Virus Testing Market Size, by Test Type, 2021–2035 (USD Million) |
TABLE 29 South America Zika Virus Testing Market Size, by Sample Type, 2021–2035 (USD Million) |
TABLE 30 South America Zika Virus Testing Market Size, by End-User, 2021–2035 (USD Million) |
TABLE 31 Middle East & Africa Zika Virus Testing Market Size, by Test Type, 2021–2035 (USD Million) |
TABLE 32 Middle East & Africa Zika Virus Testing Market Size, by Sample Type, 2021–2035 (USD Million) |
TABLE 33 Middle East & Africa Zika Virus Testing Market Size, by End-User, 2021–2035 (USD Million)
13 LIST OF FIGURES |
FIGURE 1 Global Zika Virus Testing Market Dynamics — Drivers, Restraints & Opportunities |
FIGURE 2 Value Chain Analysis — Zika Virus Testing Market |
FIGURE 3 Porter's Five Forces — Zika Virus Testing Market |
FIGURE 4 Global Zika Virus Testing Market Size Trend (USD Million), 2021–2035 |
FIGURE 5 Zika Virus Testing Market Share, by Test Type, 2025 |
FIGURE 6 Zika Virus Testing Market Share, by Sample Type, 2025 |
FIGURE 7 Zika Virus Testing Market Share, by End-User, 2025 |
FIGURE 8 Zika Virus Testing Market Share, by Region, 2025 |
FIGURE 9 North America Zika Virus Testing Market Size Trend, 2021–2035 |
FIGURE 10 Europe Zika Virus Testing Market Size Trend, 2021–2035 |
FIGURE 11 Asia-Pacific Zika Virus Testing Market Size Trend, 2021–2035 |
FIGURE 12 South America Zika Virus Testing Market Size Trend, 2021–2035 |
FIGURE 13 Middle East & Africa Zika Virus Testing Market Size Trend, 2021–2035 |
FIGURE 14 Competitive Landscape — Market Share Bubble Chart, 2025

Certified Researchers

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Test Type	Molecular Tests, Serologic Tests, PRNT	Molecular Tests	POC Molecular Assays
By Sample Type	Blood/Serum, Urine, Saliva & Others	Blood/Serum	Saliva & Others
By End-User	Hospitals & Clinics, Public-Health/Diagnostic Laboratories, Point-of-Care Settings & Home Testing, Research Institutes	Hospitals & Clinics	Point-of-Care Settings & Home Testing
By Geography	North America, Europe, Asia-Pacific, South America, Middle East & Africa	North America	Asia-Pacific

Market Segmentation Overview

By Test Type

Sub-Segment	Key Trend
Molecular Tests	Multiplex syndromic panels displacing single-analyte RT-PCR kits
Serologic Tests	Recombinant NS1 antigens improving specificity versus legacy lysate-based ELISAs
PRNT	Remaining the gold-standard confirmatory test in reference laboratory settings

Molecular tests lead global revenue as regulatory bodies increasingly mandate nucleic-acid confirmation for Zika case classification. Serologic platforms are transitioning to next-generation recombinant antigens designed to mitigate cross-reactivity with co-circulating flaviviruses.

By Sample Type

Sub-Segment	Key Trend
Blood/Serum	Standard matrix for blood-bank screening and acute-phase molecular detection
Urine	An extended viral shedding window, expanding molecular detection sensitivity
Saliva & Others	Non-invasive self-collection protocols are gaining regulatory acceptance.

Blood and serum remain the default specimen type across clinical and surveillance workflows. Saliva-based collection is attracting investment as manufacturers seek to broaden testing access through self-administered sample kits compatible with decentralized molecular platforms.

By End-User

Sub-Segment	Key Trend
Hospitals & Clinics	Integration of Zika panels into febrile-illness triage algorithms
Public-Health/Diagnostic Laboratories	Sustained procurement through national surveillance mandates
Point-of-Care Settings & Home Testing	Rapid molecular cartridges embedded in emergency-department workflows
Research Institutes	Vaccine-trial endpoint testing is driving specialized kit demand.

Hospitals and clinics anchor demand through emergency department and obstetric screening pathways. Point-of-care settings are the fastest-growing channel as health systems prioritize decentralized rapid diagnostics for outbreak-response agility.

By Geography

Sub-Segment	Key Trend
North America	Blood-bank screening mandates and state-lab molecular capacity
Europe	Returning-traveler screening and overseas-territory endemic surveillance
Asia-Pacific	National laboratory network expansion and Global Fund equipment grants
South America	PAHO-coordinated procurement and endemic-zone surveillance
Middle East & Africa	Donor-funded rapid-test distribution and Hajj pilgrim screening

North America leads in established regulatory infrastructure and automated laboratory platforms. Asia-Pacific is closing the gap as government investment in vector-borne disease diagnostics accelerates across India, Indonesia, and the Philippines.

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”